Alluvi, previously BI 4744, presents a notable breakthrough in obesity care. This dual activator targeting both GLP-1 and GIP receptors demonstrates remarkable effectiveness in research trials, possibly outperforming https://alluvihealthcare728680.smblogsites.com/profile